Chairperson’s Perspective: Reframing First-Line and Subsequent Care in Advanced Urothelial Carcinoma – Clinical Implications of the Updated NCCN Guidelines
About this episode
This episode discusses the updated NCCN Guidelines for advanced urothelial carcinoma and their clinical implications for treatment strategies.
Faculty: Jean Hoffman-Censits, MD This 15-minute online CME activity reviews the clinical implications of the updated NCCN Guidelines for advanced urothelial carcinoma (aUC), with a focus on evolving first-line and subsequent treatment strategies. The program highlights the shift away from cisplatin eligibility as the primary determinant of frontline therapy selection and examines key clinical trial data that inform current practice. Participants will explore sequencing considerations following frontline therapy as well as the role of biomarker-directed therapies in later lines of care. The activity also emphasizes early recognition and management of treatment-related adverse events alongside strategies for dose modification and supportive care. Multidisciplinary coordination and shared decision-making are discussed as essential components of optimizing patient-centered care in aUC.
More episodes of CME
- No Patient With CKD Left Behind: New Horizons in Patients With CKD Regardless of Diabetes Status
- Closing the Gaps: Global Implementation of Lipid Guidelines
- Translating Evidence Into Action: Nonsteroidal MRAs in Patients With HF
- Unblocking Clinical Inertia: The CMI Era in oHCM Care
- Chairperson’s Perspective: HER2 in Solid Tumors – From Pathology to Personalized Treatment Plans
- Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
Explore listener stats, chart rankings, contacts and more on the CME podcast page.